A peptide raised the share reaching a cell collection target to 92.5 percent

A randomised trial published in Nature Medicine in 2023 reported one of the wider gaps in recent haematology: 92.5 percent of one group met the trial's main measurement against 26.2 percent of the other. Three years later the first published comparison against the treatment already in routine use reported no advantage at all. Both are about the same peptide, and the distance between them is a lesson about what a large effect against a placebo does and does not establish [1][2].

What the procedure is

People with multiple myeloma, a cancer of the plasma cells in bone marrow, are often treated with a transplant of their own blood stem cells. The cells are collected first, then given back after high strength chemotherapy has cleared the marrow. To collect them, the cells have to be coaxed out of the bone marrow into the bloodstream, which is done with a growth factor injection over several days. The blood is then passed through a machine that separates out the stem cells, a procedure called apheresis, and returns everything else [1].

The procedure has a threshold. Transplant teams aim for around six million of a particular kind of stem cell for every kilogram of the patient's body weight. Many patients do not reach it with the growth factor alone and have to return for further sessions, each of which takes hours [1].

The peptide and the trial

Motixafortide is a cyclic peptide, a short chain of amino acids joined into a ring, that blocks a receptor called CXCR4. That receptor is part of what tethers stem cells inside the bone marrow, so blocking it releases them into the blood. The GENESIS trial enrolled 122 adults at 18 sites in five countries and assigned them by chance, two to one, to the peptide plus the growth factor or to an inactive substitute plus the growth factor. Neither patients nor staff knew which was which [1].

The main measurement was the share of patients who collected the target number of cells within two apheresis sessions. In the peptide group 92.5 percent did, against 26.2 percent in the placebo group, with a P value below 0.0001. The secondary measurement, reaching the target in a single session, was met by 88.8 percent against 9.5 percent [1].

Side effects were mostly local and short lived: pain at the injection site in 50 percent, redness in 27.5 percent and itching in 21.3 percent, all reported as mild or moderate. The peptide was approved in the United States on 11 September 2023, for use alongside the growth factor in this exact situation. It is developed by BioLineRx under licence from Biokine Therapeutics [1][3].

What the trial measured, and what it did not

The measurement is the number of cells collected. That is a real and useful thing to measure, because a patient who reaches the target in one session avoids returning for more, and because failing to collect enough can delay or prevent a transplant altogether. It is not a measurement of how the transplant went, how long the cancer stayed away, or how long anyone lived. The trial did not follow patients for those things, and no figure in it speaks to them [1].

The comparison also deserves attention. The trial compared the peptide plus growth factor against growth factor alone. It did not compare it against plerixafor, the drug already used for this job when the growth factor is not enough. Against an inactive substitute, the gap was enormous. Against the existing option, the trial says nothing, because the existing option was not in it [1].

The first head to head look

That gap in the record was partly filled in 2026, by a report in Transfusion from a single centre that compared 30 patients given the peptide with 30 matched patients given the older drug, one group followed forward and one drawn from records. The stem cell yields were similar. The time each session took was similar. Twenty seven patients in each group reached the target in one day [2].

What differed was tolerability and workload. Reactions needing treatment were substantially more common with the peptide, both at the injection site and throughout the body, and it required medicine given beforehand and monitoring afterwards. The centre concluded that the peptide was workable but not superior, kept the older drug as its default, and reserved the peptide for selected patients [2].

Sixty patients at one hospital, with one group taken from past records, is a weaker design than a randomised trial and cannot overturn one. It is also the only direct comparison published so far, and it points the opposite way from what the size of the placebo controlled result would lead a reader to expect.

Why both belong in the summary

A very large effect against a placebo establishes that the drug does what it was designed to do. It says nothing about where the drug sits among the options a clinic already has, and nothing about whether the patients ended up better off. Those are separate questions, and each one needs a trial built to answer it [1][2].

What would settle it

A randomised comparison against the existing drug, in enough patients to detect a difference, reporting what happened after the transplant rather than only what came out of the collection machine. Until that exists, the defensible reading of this record is that the peptide reliably releases stem cells into the blood, and that whether it is the better choice for a given patient remains open [1][2][3].